Comparison · NCT04425629-69785e91
Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization or All-cause Death From Day 4 Through Day 29 (Ph3 Cohort 1 - 2.4g vs. Placebo)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization or All-cause Death From Day 4 Through Day 29 (Ph3 Cohort 1 - 2.4g vs. Placebo). Trial comparisons, record NCT04425629-69785e91. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04425629-69785e91
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0037 | 0.00158 | 0.00863 | wilson | |
| Risk in group 2 | 0.0343 | 0.0258 | 0.0455 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0306 | -0.042 | -0.0208 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.108 | 0.043 | 0.27 | log | |
| Odds ratio, group 1 over group 2 | 0.104 | 0.0414 | 0.264 | log | |
| Number needed to treat, for one fewer participant with the outcome on Phase 3 Cohort 1 (2.4g IV) >= 18 than on Phase 3 Cohort 1 (Placebo) >=18 | 32.7 | 23.8 | 48.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase 3 Cohort 1 (2.4g IV) >= 18 | Phase 3 Cohort 1 (2.4g IV) | 5 | 1,351 | OG001 |
| Group 2 | Phase 3 Cohort 1 (Placebo) >=18 | Phase 3 Cohort 1 (Placebo) | 46 | 1,340 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Proportion of Participants With ≥1 COVID-19-related Hospitalization or All-cause Death From Day 4 Through Day 29 (Ph3 Cohort 1 - 2.4g vs. Placebo)
- Description
- Phase 3 (Cohort 1)
- Time frame
- From Day 4 Through Day 29
- Population
Participants that were ≥18 years old and not pregnant at randomization, and randomized on or before 17-Jan-2021 with detectable SARS-CoV-2 RNA by RT-qPCR in nasopharyngeal swabs at randomization and at least 1 risk factor for severe COVID-19 at baseline
Source ClinicalTrials.gov
Trial
- Title
- Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19
- NCT number
- NCT04425629
- Phases
- PHASE3
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab combination therapy
- Lead sponsor
- Regeneron Pharmaceuticals
- Results first posted
- 2023-12-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04425629?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04425629-69785e91